REFERENCES
- Center for Drug Evaluation and Research. 2015. IND application procedures: Exemptions from IND Requirements. U.S. Food and Drug Administration. https://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-application-procedures-exemptions-ind-requirements (accessed December 19, 2019).
- Centers for Disease Control and Prevention. 2019. Administering MMR vaccine” https://www.cdc.gov/vaccines/vpd/mmr/hcp/administering-mmr.html (accessed December 19, 2019).
- Field, M. J., and R. E., Behrman, eds. 2004. Ethical conduct of clinical research involving children, Institute of Medicine (US) Committee on Clinical Research Involving Children. Washington (DC): National Academies Press. https://www.ncbi.nlm.nih.gov/books/NBK25542/. (accessed December 19, 2019).
- Food and Drug Administration. 2019. 21 CFR §312. Investigational new drug application. Revised April 1. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.2 (accessed December 19, 2019).
- Johnson, L. M., D. M. Duenas, and B. Wilfond. 2020. Greater than minimal risk, no direct benefit: Bridging drug trials and novel therapy in pediatric populations. The American Journal of Bioethics 20(4):102–103.
- Kanter, J., and R. Kruse-Jarres. 2013. Management of sickle cell disease from childhood through adulthood. Blood Reviews 27(6): 279–287.
- Lagresle-Peyrou, C., F. Lefrère, E. Magrin, et al. 2018. Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion. Haematologica 103(5): 778–786.
- Quinn, C. T. 2013. Sickle cell disease in childhood: From newborn screening through transition to adult medical care. Pediatric Clinics of North America 60(6): 1363–1381.
- U.S. Department of Health and Human Services. 2018. Final rule 45 CFR §46. Protection of human subjects. Revised July 19. https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html (accessed December 19, 2019).
- Ware, R. E., P. T. McGann, and C. T. Quinn. 2019. Hydroxyurea for children with sickle cell anemia: Prescribe it early and often. Pediatric Blood and Cancer 66(8): e27778.
- Wendler, D., and E. J. Emanuel. 2005. What is a “minor” increase over minimal risk? The Journal of Pediatrics 147(5): 575–578.